Nonetheless, it is interesting to note that non-insulin glucose-lowering drugs, not only DPP4 inhibitors and SGLT2 inhibitors but also GLP1 analogues, are starting to be used in hospital diabetes management. This evidence concerns the gene SLC5A2 and diabetes mellitus.